Jiangsu Gdk Biological Technology Co., Ltd (SHSE: 688670)
Health Care · Biotechnology · CN
CN¥16.01
+2.30% today · -1.7% 1Y
Jiangsu Gdk Biological Technology Co., Ltd (SHSE: 688670) operates in the Biotechnology industry within the Health Care sector. The company is valued at $292.45M and employs 390 people.
Over the last twelve months the share price has lost 1.7%, trading between 12.50 and 31.20.
Tweenvest scores Jiangsu Gdk Biological Technology Co., Ltd across four factors: quality 49/100, value 66/100, growth 0/100. Its strongest factor is value.
688670 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $292.45M
- Revenue (TTM)
- $15.99M
- P/E
- —
- EPS
- -1.49
- Dividend yield
- —
- Beta (5Y)
- 0.25
- 52-week high
- CN¥31.20
- 52-week low
- CN¥12.50
- Avg volume (3M)
- —
- Shares outstanding
- 123.20M
- Employees
- 390
- Next earnings
- —
About Jiangsu Gdk Biological Technology Co., Ltd
Jiangsu gdk Biotechnology Co., Ltd. operates as a biotechnology firm specializing in the comprehensive research, development, manufacturing, and commercialization of human vaccines, alongside providing related services. Its current portfolio includes a quadrivalent split-virus influenza vaccine and a lyophilized human rabies vaccine. The company's pipeline is strategically focused on preventing major infectious diseases such as influenza, rabies, chickenpox, shingles, and pneumonia. This enterprise was established in 2008 and is headquartered in Taizhou, China.
- Founded
- 2008
- Listed since
- Aug 2, 2021
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €884.60 | -1.93% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.